Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus
carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced
pulmonary large cell neuroendocrine carcinoma.